Parasal sodium, Granupas (previously para-aminosalicylic acid lucane)(aminosalicylic acid)
Granupas, Neopasalate, Parasal, Rezipas (aminosalicylic acid) is a small molecule pharmaceutical. Aminosalicylic acid was first approved as Parasal sodium on 1982-01-01. It is used to treat crohn disease and tuberculosis in the USA. It has been approved in Europe to treat tuberculosis. The pharmaceutical is active against peroxisome proliferator-activated receptor gamma.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aminosalicylate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PARASAL SODIUM | Panray Corporation | N-006811 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Aminosalicylic acid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PARASAL | Panray Corporation | N-006811 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Aminosalicylic acid resin complex
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| REZIPAS | Bristol Myers Squibb | N-009052 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| crohn disease | EFO_0000384 | D003424 | K50 |
| tuberculosis | EFO_0000774 | D014376 | A15-A19 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EC: Aminosalicylic acid and similar agents
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AA: Aminosalicylic acid and derivatives
— J04AA01: 4-aminosalicylic acid
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 2 | 5 | 1 | 1 | 8 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | 1 | 2 | 4 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | — | 1 | 1 | 4 |
| Immune system diseases | D007154 | D89.9 | — | — | — | 1 | — | 1 | |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | — | 1 |
| Sexually transmitted diseases | D012749 | A50-A64 | — | — | — | 1 | — | 1 | |
| Lentivirus infections | D016180 | EFO_1001357 | — | — | — | 1 | — | 1 | |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | 1 | — | 1 | |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fecal microbiota transplantation | D000069467 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AMINOSALICYLIC ACID |
| INN | — |
| Description | 4-aminosalicylic acid is an aminobenzoic acid that is salicylic acid substituted by an amino group at position 4. It has a role as an antitubercular agent. It is an aminobenzoic acid and a member of phenols. It is functionally related to a salicylic acid. It is a conjugate acid of a 4-aminosalicylate(1-). |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(C(=O)O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 65-49-6 |
| RxCUI | 7833 |
| ChEMBL ID | CHEMBL1169 |
| ChEBI ID | 27565 |
| PubChem CID | 4649 |
| DrugBank | DB00233 |
| UNII ID | — |
Target
Agency Approved
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,816 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
67,065 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more